LADX / LadRx Corporation - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LADRX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LADRX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 LADRX CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (

Insider Trading Policy of LadRx Corporation

Exhibit 19.1 CYTRX CORPORATION STATEMENT OF POLICY ON SECURITIES TRADING BY COMPANY PERSONNEL January 2022 Introduction CytRx Corporation has adopted this Statement of Policy on Securities Trading by Company Personnel (“Policy Statement”) governing securities transactions by employees of CytRx Corporation and its subsidiaries (collectively, with CytRx Corporation, the “Company”). The Insider Tradi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corpo

First Amendment of Royalty Purchase Agreement, dated as of June 3, 2024, by and between LadRx Corporation and XOMA (US) LLC

Exhibit 10.2

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License Aldoxorubicin Returns to LadRx

Exhibit 99.1 LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License Aldoxorubicin Returns to LadRx Los Angeles, CA, June 3, 2024 – (BUSINESS WIRE) — LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 LADRX CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Num

Mutual Termination and Release Agreement, dated as of June 3, 2024, by and among LadRx Corporation, NantCell, Inc., ImmunityBio, Inc. and XOMA (US) LLC

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (Ex

Employment Agreement, dated December 30, 2022, by and between LadRx Corporation and Dr. Stephen Snowdy.

Exhibit 10.15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (

Employment Agreement, dated December 30, 2022, by and between LadRx Corporation and John Y. Caloz

Exhibit 10.16

LadRx Corporation

EXHIBIT 21.1 LadRx Corporation Subsidiaries (all 100% owned) Subsidiaries of the Registrant State or Other Jurisdiction of Incorporation Delaware

LADX / LadRx Corporation / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporat

Certificate of Amendment of Restated Certificate of Incorporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF LADRX CORPORATION LadRx Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 LADRX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

Amendment No. 1 to LadRx Corporation 2019 Stock Incentive Plan

Exhibit 10.1 First AMENDMENT TO LADRX CORPORATION 2019 Stock incentive plan This first Amendment To LADRX CORPORATION 2019 STOCK INCENTIVE Plan (this “Amendment”), effective as of September 7, 2023, is made and entered into by LadRx Corporation, formerly known as CytRx Corporation, a Delaware corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherw

Amendments to the By-Laws

Exhibit 3.2 AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF LADRX CORPORATION Pursuant to Article Eighth of the Restated Certificate of Incorporation of LadRx Corporation, a Delaware corporation (the “Company”), and Section 109 of the General Corporation Law of the State of Delaware, on the date hereof, (i) Article III, Section 3, and (ii) Article III Section 5 of the Amended and Restated By-laws

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ☐ Definitive

Royalty Purchase Agreement dated June 21, 2023, by and between LadRx Corporation and XOMA (US) LLC

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. Royalty Purchase Agreement By and Between LadRx Corporation and XOMA (US) LLC Dated as of June 21, 2023 Table of Contents Page Article 1 DEFINED TERMS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 LADRX CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets

Exhibit 99.1 LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assets LOS ANGELES, June 22, 2023 – (BUSINESS WIRE) – LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused o

Assignment and Assumption Agreement, dated June 21, 2023, by and between LadRx Corporation and XOMA (US) LLC

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. ASSIGNMENT AND ASSUMPTION AGREEMENT This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of June 21, 2023 (the “Closing Date”), is ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (Ex

LadRx Announces Reverse Stock Split

Exhibit 99.1 LadRx Announces Reverse Stock Split LOS ANGELES—(BUSINESS WIRE)—LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares. The reverse

Certificate of Amendment of Restated Certificate of Incorporation

Exhibit 3.1 Certificate of Amendment of Restated Certificate of Incorporation of LADRX Corporation LadRx Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on Febr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 LADRX CORPORATION (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Numb

As Filed with the Securities and Exchange Commission on April 14, 2023

As Filed with the Securities and Exchange Commission on April 14, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) LADRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2)(3) Fee Rate Amount of Registration Fee Fees to be paid Equity Units, each unit consisting of (i) one share of common stock, par value $0.

LadRx Corporation

EXHIBIT 21.1 LadRx Corporation Subsidiaries (all 100% owned) Subsidiaries of the Registrant State or Other Jurisdiction of Incorporation Centurion BioPharma Corporation Delaware

Employment Agreement, dated December 30, 2022, by and between LadRx Corporation and John Y. Caloz

Exhibit 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into this 30th day of December, 2022, with an effective date of January 1, 2023 (the “Effective Date”) by and between LadRx Corporation, a Delaware corporation (the “Company”), and John Caloz (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive, and the Executive is wi

Employment Agreement, dated December 30, 2022, by and between LadRx Corporation and Dr. Stephen Snowdy.

Exhibit 10.15 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into this 30th day of December, 2022, with an effective date of January 1, 2023 (the “Effective Date”) by and between LadRx Corporation, a Delaware corporation (the “Company”), and Stephen Snowdy (the “Executive”). WHEREAS, the Company desires to continue to employ the Executive, and the Executive i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation (

CYTR / CytRx Corporation / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 LADRX CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 LADRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 LadRx Corporation

CytRx Corporation Relaunches as LadRx Corporation The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA

Exhibit 99.1 CytRx Corporation Relaunches as LadRx Corporation The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA LOS ANGELES?(BUSINESS WIRE)?CytRx Corporation (OTCQB: CYTR) (?CytRx? or the ?Company?), a biopharmaceutical innovator focused on research and development of life-saving

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fi

Certificate of Amendment of Restated Certificate of Incorporation

Exhibit 3.1 Certificate of Amendment of Restated Certificate of Incorporation of CytRx CORPORATION CytRx Corporation (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The original Certificate of Incorporation of this Corporation was filed with the Secretary of State of Delaware on Febr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 CytRx Corporation (Exa

Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020 and Amendment No. 1 to the Amended and Restated Bylaws of dated May 19, 2022.

Exhibit 3.3 AMENDED AND RESTATED BY-LAWS OF CYTRX CORPORATION (a Delaware Corporation) REFLECTING AMENDMENTS THROUGH NOVEMBER 12, 2020 ARTICLE I CAPITAL STOCK 1. CERTIFICATED OR UNCERTIFICATED SHARES OF STOCK. Shares of stock in CytRx Corporation (the ?Corporation?) shall be represented by certificates, or shall be uncertificated, as determined by the Board of Directors of the Corporation (the ?Bo

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Num

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Num

Certificate of Designation of Series D Preferred Stock

Exhibit 3.1 CytRx Corporation CERTIFICATE OF DESIGNATION OF SERIES D PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned does hereby certify, on behalf of CytRx Corporation, a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the board of directors of the Corporation (the ?Board of Directors?), in

CytRx Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Exhibit 99.1 CytRx Announces Distribution of Series D Preferred Stock to Holders of its Common Stock LOS ANGELES May 19, 2022, CytRx Corporation (OTCQB: CYTR) (?CytRx? or the ?Company?), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly desig

Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020 and Amendment No. 1 to the Amended and Restated Bylaws of dated May 19, 2022.

EXHIBIT 3.3 STATE OF DELAWARE CERTIFICATE OF CORRECTION CytRx Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The name of the corporation is CytRx Corporation. 2. That a Certificate of Amendment to Restated Certificate of Incorporation of CytRx Corporation (the ?Certificate?) was filed

Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020 and Amendment No. 1 to the Amended and Restated Bylaws of dated May 19, 2022.

eXHIBIT 3.2 Amendment to the Amended and Restated By-laws of CytRx Corporation Pursuant to Article Ninth of the Restated Certificate of Incorporation of CytRx Corporation, a Delaware corporation (the ?Company?), Article VIII of the Amended and Restated By-laws of the Company (as amended heretofore, the ?By-laws?) of the Corporation, and Section 109 of the General Corporation Law of the State of De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CytRx Corporation (Exact name of registrant a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CytRx Corporation (Exact name of registrant as specified in its charter) Delaware 58-1642740 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 11726

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 CytRx Corporat

CytRx Corporation 20,727,274 Shares of Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-258453 PROSPECTUS CytRx Corporation 20,727,274 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus from time to time of up to 20,727,274 shares of our common stock, par value $0.001 per share. These 20,727,274 shares of common stock consist of: ? up to an aggregate of 9,363,637 shares

Employment Agreement, dated December 16, 2021, by and between CytRx Corporation and John Y. Caloz

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into this 16th day of December, 2021, with an effective date of January 1, 2022 (the ?Effective Date?) by and between CytRx Corporation, a Delaware corporation (?Employer?), and John Caloz, an individual and resident of the State of California (?Executive?). WHEREAS, Employer desires to continue to e

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-1 ????.. (Form Type) CytRx Corporation ????????????????????..? (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-15327 CytRx Corporation (

As Filed with the Securities and Exchange Commission on March 23, 2022

As Filed with the Securities and Exchange Commission on March 23, 2022 Registration No.

CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049

CORRESP 1 filename1.htm CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 March 23, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Re: CytRx Corporation Registration Statement on Form S-1, as amended Initially filed on August 4, 2021, as ame

Subsidiary List of CytRx Corporation

EXHIBIT 21.1 CytRx Corporation Subsidiaries (all 100% owned) Subsidiaries of the Registrant State or Other Jurisdiction of Incorporation Centurion BioPharma Corporation Delaware

Description of Securities

Exhibit 4.4 Description of Securities The following description is intended as a summary and is qualified in its entirety by reference to our Restated Certificate of Incorporation, as amended (the ?Certificate of Incorporation?) and our Amended and Restated By-Laws (the ?By-laws?) as currently in effect, copies of which are filed as exhibits to this Amendment No. 1 to the Annual Report on Form 10-

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress Thanks Stockholders for Supporting Important Proposal at Recent Special Meeting

Exhibit 99.1 CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress Thanks Stockholders for Supporting Important Proposal at Recent Special Meeting LOS ANGELES?(BUSINESS WIRE)?CytRx Corporation (OTCQB: CYTR) (?CytRx? or the ?Company?), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockho

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File N

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File N

Certificate of Amendment of Restated Certificate of Incorporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF CYTRX CORPORATION CytRx Corporation (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: FIRST: The Restated Certificate of Incorporation of the Corporation is hereby amended by deleting in its entirety th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates Believes Integration Will Bring Enhanced Efficiency and Simplicity to the Company’s Structure Notes the Company Will Fold Centurion into CytRx

Exhibit 99.1 CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates Believes Integration Will Bring Enhanced Efficiency and Simplicity to the Company?s Structure Notes the Company Will Fold Centurion into CytRx Dr. Louis Ignarro, Chairman of the Compensation Committee, to Retire from the Board as of the July 2022 Annual Meeting Steven Kriegsman

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares

Exhibit 99.1 FAQ on Issuance of Shares to Armistice Capital and Special Meeting of Shareholders to Approve Increase in Authorized Shares February 17, 2022 Why did CytRx issue common and preferred shares to Armistice Capital? Following the announcement from Orphazyme in June 2021 that arimoclomol for Niemann-Pick Disease had not been granted FDA approval, the Board determined that a lack of action

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of CytRx Corporation. This Joint Filing Agreement sh

CYTR / CytRx Corporation / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive

Please Protect Our Assets and Help Your Company Avoid Running out of Cash by Voting FOR the Proposal at the Upcoming Special Meeting

Exhibit 99.1 Dear Valued Stockholder, I began as the new Chief Executive Officer of CytRx Corporation (?CytRx? or the ?Company?) on January 10, 2022. I joined the Company after the Board of Directors (the ?Board?) ran an independent process that was led by a top-tier executive recruiting firm that screened dozens of candidates. As a cancer survivor, finding new treatments and cures for cancer is v

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) ? Definitive

CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer Dr. Snowdy to Succeed Steven A. Kriegsman, Who is Stepping Down as CEO and Chairman of the Board

Exhibit 99.1 CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer Dr. Snowdy to Succeed Steven A. Kriegsman, Who is Stepping Down as CEO and Chairman of the Board LOS ANGELES?(BUSINESS WIRE)?CytRx Corporation (OTCQB:CYTR) (?CytRx? or the ?Company?), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, to

General Release and Separation Agreement, dated January 3, 2022, by and between CytRx Corporation and Steven A. Kriegsman.

Exhibit 10.2 GENERAL RELEASE AND SEVERANCE AGREEMENT This General Release and Severance Agreement (the ?Agreement?), dated as of January 3, 2022, is made and entered into by and between Steven Kriegsman (?Executive?) and CytRx Corporation (?CytRx?). For good and valuable consideration, receipt of which is hereby acknowledged, in order to effect a mutually satisfactory and amicable separation of em

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

Employment Agreement, dated January 3, 2022, by and between CytRx Corporation and Dr. Stephen Snowdy

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into this 3rd day of January, 2022, with an effective date of January 10, 2022 (the ?Effective Date?) by and between CytRx Corporation, a Delaware corporation (?Employer?), and Dr. Stephen Snowdy, an individual and resident of the State of Georgia (?Executive?). WHEREAS, Employer desires to employ Ex

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

Amendment No. 1 to the Cooperation Agreement, dated September 2, 2021, by and between CytRx Corporation and Jerald A. Hammann

Execution Version Exhibit 10.1 AMENDMENT NO. 1 TO COOPERATION AGREEMENT This Amendment No. 1 to the Cooperation Agreement (this ?Amendment?), effective as of September 2, 2021, amends the Cooperation Agreement, (the ?Agreement?) effective as of August 21, 2020, by and between CytRx Corporation, a Delaware corporation (the ?Company?), and Jerald A. Hammann and his Affiliates (collectively, ?Hammann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant ?[ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) [X]

As Filed with the Securities and Exchange Commission on August 4, 2021

S-1 1 forms-1.htm As Filed with the Securities and Exchange Commission on August 4, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 2834 58-1642740 (State or other jurisdiction of incorporation or organization) (Primary Stand

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors

Exhibit 99.1 CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors July 29, 2021 04:05 PM Eastern Daylight Time LOS ANGELES?(BUSINESS WIRE)?CytRx Corporation (OTCQB: CYTR) (?CytRx? or the ?Company?), a specialized biopharmaceutical company focused on research and development for the oncology and neu

Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant ?[ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) [ ]

2,000,000 Shares of Common Stock

PROSPECTUS SUPPLEMENT (To the Prospectus Dated July 12, 2021) Filed Pursuant to Rule 424(b)(5) Registration No.

Form of Securities Purchase Agreement, dated as of July 13, 2021, by and between the Company and the purchaser thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 13, 2021, between CytRx Corporation, a Delaware corporation (the ?Company?), and the purchaser identified on the signature page hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to (i

Form of Preferred Investment Option

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Certificate of the Designations, Powers, Preferences and Rights of Series C 10.00% Convertible Preferred Stock

EX-3.1 2 ex3-1.htm Exhibit 3.1 CERTIFICATE OF THE DESIGNATIONS, POWERS, PREFERENCES AND RIGHTS OF SERIES C 10.00% CONVERTIBLE PREFERRED STOCK OF CYTRX CORPORATION (Pursuant to Section 151 of the Delaware General Corporation Law) CytRx Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), hereby certifies that, pursuant to authority vested in the

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

Form of Registration Rights Agreement, dated as of July 13, 2021, by and between the Company and the purchaser thereto

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 13, 2021, between CytRx Corporation, a Delaware corporation (the ?Company?), and the purchaser identified on the signature page hereto (the ?Purchaser?). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Co

CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor

EX-99.1 7 ex99-1.htm Exhibit 99.1 CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor LOS ANGELES, July 13, 2021—(BUSINESS WIRE)—CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1

10-K/A 1 form10ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi

Description of Securities

Exhibit 4.3 Description of Securities The following description is intended as a summary and is qualified in its entirety by reference to our Restated Certificate of Incorporation, as amended (the ?Certificate of Incorporation?) and our Amended and Restated By-Laws (the ?By-laws?) as currently in effect, copies of which are filed as exhibits to this Amendment No. 1 to the Annual Report on Form 10-

CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049

CORRESP 1 filename1.htm CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 July 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Re: CytRx Corporation Registration Statement on Form S-3, as amended Filed on April 22, 2021 File No. 333-25543

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 formdef14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy St

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 CYTRX CORPORATION (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on May 14, 2021 Reg. No. 333-255431 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1642740 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327

-

S-3 1 forms-3.htm As filed with the Securities and Exchange Commission on April 22, 2021 Reg. No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1642740 (State or other jurisdiction of incorporation or organization) (I.R

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation

Fifth Amendment to Office Lease dated January 13, 2020 by and between CytRx Corporation and Douglas Emmett 1993, LLC

Exhibit 10.3.2

Employment Agreement, dated January 8, 2021, by and between CytRx Corporation and John Y. Caloz

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into this 5th day of January, 2021, with an effective date of January 1, 2021 (the ?Effective Date?) by and between CytRx Corporation, a Delaware corporation (?Employer?), and John Caloz, an individual and resident of the State of California (?Employee?). WHEREAS, Employer desires to continue to empl

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

Amended and Restated Certificate of Designation of Series B Junior Participating Preferred Stock of CytRx Corporation.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES B JUNIOR PARTICIPATING PREFERRED STOCK OF CYTRX CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware CytRx Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Company”), DOES HEREBY CERTIFY: That, pursuant to authority conf

Amended and Restated Rights Agreement, dated as of November 16, 2020, by and between CytRx Corporation and American Stock Transfer & Trust Company, as Rights Agent.

Exhibit 4.1 CYTRX CORPORATION and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent AMENDED AND RESTATED RIGHTS AGREEMENT dated as of November 16, 2020 TABLE OF CONTENTS Page Section 1. Certain Definitions. 1 Section 2. Appointment of Rights Agent. 11 Section 3. Issue of Rights Certificates. 11 Section 4. Form of Rights Certificate. 13 Section 5. Countersignature and Registration. 14 S

Form 8-A/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Number)

Amended and Restated Rights Agreement, dated as of November 16, 2020, by and between CytRx Corporation and American Stock Transfer & Trust Company, LLC, as rights agent

Exhibit 4.1 CYTRX CORPORATION and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent AMENDED AND RESTATED RIGHTS AGREEMENT dated as of November 16, 2020 TABLE OF CONTENTS Page Section 1. Certain Definitions. 1 Section 2. Appointment of Rights Agent. 11 Section 3. Issue of Rights Certificates. 11 Section 4. Form of Rights Certificate. 13 Section 5. Countersignature and Registration. 14 S

Amended and Restated By-Laws of CytRx Corporation, effective November 12, 2020

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF CYTRX CORPORATION (a Delaware Corporation) REFLECTING AMENDMENTS THROUGH NOVEMBER 12, 2020 Article I CAPITAL STOCK 1. CERTIFICATED OR UNCERTIFICATED SHARES OF STOCK. Shares of stock in CytRx Corporation (the “Corporation”) shall be represented by certificates, or shall be uncertificated, as determined by the Board of Directors of the Corporation (the “Bo

Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES B JUNIOR PARTICIPATING PREFERRED STOCK OF CYTRX CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware CytRx Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Company”), DOES HEREBY CERTIFY: That, pursuant to authority conf

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

Quarterly Report -

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-1

-

As filed with the Securities and Exchange Commission on October 23, 2020 Registration No.

Form of Non-qualified Stock Option Grant under 2019 Stock Incentive Plan

Exhibit 4.8 CYTRX CORPORATION 2019 STOCK INCENTIVE PLAN GRANT NOTICE We are pleased to inform you that you have been awarded the following Stock Option (the “Option”) under the CytRx Corporation 2019 Stock Incentive Plan (the “Plan”) on the following terms: Name of Participating Optionee: Grant No. Total Number of Shares Awarded: [] Non-Qualified Stock Options Exercise price: $ Grant date: Vesting

CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation Highlights That Stockholders Have Voted to Re-Elect Steven A. Kriegsman and Dr. Louis Ignarro to the Board Releases New Presentation Summarizing the Company’

Exhibit 99.1 CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation Highlights That Stockholders Have Voted to Re-Elect Steven A. Kriegsman and Dr. Louis Ignarro to the Board Releases New Presentation Summarizing the Company’s Strategic Priorities and Path to Delivering Long-Term Value for Stockholders September 3, 2020 CytRx Corporation (OTCQB: CYTR) (“CytRx”

Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

NOTICEPAPERS WEBSITE FROM AUGUST 24, 2020 -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Cooperation Agreement, dated August 21, 2020, by and between CytRx Corporation and Jerald A. Hammann

Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), effective as of August 21, 2020 (the “Effective Date”), is entered into by and between CytRx Corporation, a Delaware corporation (the “Company”), and Jerald A. Hammann and his Affiliates (collectively, “Hammann”). The Company and Hammann are together referred to herein as the “Parties,” and each, a “Party.” Unless ot

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

- 2020 NOTICE OF WITHDRAWAL FROM PROXY CONTEXT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

August 24, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that

Exhibit 99.1 CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input Augments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their Current

- E-MAIL TO FORMER SHAREHOLDERS OF CYTRX CORPORATION

DFAN14A 1 email20200818.htm E-MAIL TO FORMER SHAREHOLDERS OF CYTRX CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Ame

DFAN14A 1 npws20200702t0817.htm NOTICEPAPERS WEBSITE FROM JULY 2, 2020 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Regist

NOTICEPAPERS WEBSITE FROM JULY 2, 2020 - (WEBSITE PDF)

- 2020 SECOND LETTER TO SHAREHOLDERS AUTHORED BY JERALD HAMMANN (PDF)

begin 644 letterHammann20200817filing.pdf M)5!$1BTQ+C0*)=/KZ>$*,2 P(&]B:@H\/"]#+/1.K1A]^.:P9& M&M4F:VUC54BMC=DU7[98UMM8E(Q[)][^FZ6649W>Q^?W0'/[X M\FGSYH-M/OV[VOBCW)K*J&ZB";N9NUO*!6/&%Z)Q MPPN/3YLW[\M+V-::PXZ?/I:7V%-!-U:G-IFD;6-4\1Y\Y-2-OW7SSDB$3>IF/#;/M(21&]SF*%5 M:T/91;Z0+,D^'O!9],*X0Y0/0VM8=1@I'$G:)9TK1D!V4 M1SJ>?P^^JZW3- M*M.:'-+.*O:Z]G#<3'8NF1-IW(%A.]M<%BOFO1P8>KMW"-LQFT[GD15!@;, M\IIF/-#*!\EV

- 2020 SECOND LETTER TO SHAREHOLDERS AUTHORED BY JERALD HAMMANN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (E

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P

- 2020 LETTER TO SHAREHOLDERS AUTHORED BY JERALD HAMMANN (PDF)

begin 644 letterHammann20200812filing.pdf M)5!$1BTQ+C0*)=/KZ>$*,2 P(&]B:@H\/"]#+/1.K1A]^.:P9& M&M4F:VUC54BMC=DU7[98UMM8E(Q[)][^FZ6649W>Q^?W0'/[X M\FGSYH-M/OV[VAT"'=7U.[6PQEUM3XJ)MHPF[F[I9RP9CQA6C< M\,+CT^;-^(2MK7FL..GC^4E]E30C=6I329IVQC5/'W>*2433\W3W]MX'?*M3]*?;XYJ>7Y6.6MSNCW10(0%E-T/E"U8XU(^ M+1'VUV/KM'4YYO.U8YM5H:9.IR5F'<(SAN)CN7S(DT[L"PG6TNBQ7SW@X,/5V[A$VX[8=3Z(J P-F M>4TS'FCE@V2[UMF4D]*G 4,S:

- 2020 CONTESTED PROXY STATEMENT - DEFINITIVE FIRST AMENDED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid

- 2020 LETTER TO SHAREHOLDERS AUTHORED BY JERALD HAMMANN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

- 2020 CONTESTED PROXY STATEMENT - DEFINITIVE FIRST AMENDED (PDF)

begin 644 defn14aHammannA1.pdf M)5!$1BTQ+C0*)=/KZ>$*,2 P(&]B:@H\/"]#+/1.K1A]^.:P9& M&M4F:VUC54BMC=DU7[98UMM8E(Q[)][^FZ6649W>Q^?W0'/[X M\FGSYH-M/OV[VP]E'M3XZ-NH@F[J;M;R@5CQA>B M<<,+CT^;-^+6]C6FL.6GSZ6M]B303=6IS:9I&UC5//T>?.34C;]W#S]M6LS>GV1 ,1%E!V/U"V8(U+ M^;1$V%^/K=/6Y9C/UXYM5CHXG4Y+N&[M8*-VX8J7[=9^]S1#86-BFWRVJ;&A MIS"]-E,F$$^067XE9DW>/D>5RZUU+#2MSR$GE\\Y(A$WJ9CPVS[2$D1OE3P.&9M :ZOVTI* $D5)I+10YF

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,

August 7, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,

- 2020 CONTESTED PROXY STATEMENT - FOURTH AMENDED REDLINE

begin 644 prrn14aHammannA4redline.pdf M)5!$1BTQ+C,*)<3E\N7KI.@T,3&"C0@,"!O8FH*/#P@+TQE;F=T:" U(# @ M4B O1FEL=&5R("]&;&%T941E8V]D92 ^/@IS=')E86T*> '-7-N2W+81?>=7 MT+KMK*VE"-X9.=%*\JY64N+(RL9.G/63*HXK):7*\?]7Y?0-%Y(SPYG10VJK ME@,0 !N-QNF#!LA?\^R7,G+W]S^8??\I+?ON K+*H&DG3#S?D[3 68Y5 M^)2N,TORJ(LVRZ9 W%1?#Q95U70QME;=EG=U^RI^^>+> M?/\HLXW#QX^.L.O)M<;7!UR+D[?"0$CEMVRJUL6:2@NJBE!;Y&IFH]WNY$$NSZ2QRR-UU[BV

- 2020 CONTESTED PROXY STATEMENT - FOURTH AMENDED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 4) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid

- 2020 CONTESTED PROXY STATEMENT - THIRD AMENDED

PRRN14A 1 prrn14aHammannA3.htm 2020 CONTESTED PROXY STATEMENT - THIRD AMENDED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant ☐ Filed by a Party other than the

- 2020 CONTESTED PROXY STATEMENT - THIRD AMENDED REDLINE

begin 644 prrn14aHammannA3redline.pdf M)5!$1BTQ+C,*)<3E\N7KI.@T,3&"C0@,"!O8FH*/#P@+TQE;F=T:" U(# @ M4B O1FEL=&5R("]&;&%T941E8V]D92 ^/@IS=')E86T*> '-7&ESW,818Y? M >OB,O:"&-R(G(@40UJ68L>*F#@'4D5QY624N7XU?E]34'@%UB=U65E$H+ M]&"FT3/3\J8 7.W^8YQ?7O[C\2]YR?]^>8^BLJ@:H>GD[C,58Y>\ MYBO\FU9E&7;Y7?O\Z;B:KBXLJZ+H:WRMJRSNXYQ=T="O.['.YYO/'CT^ MS[=UOGGR]-D9[II\<[!U:'DOS)4R)^R.]>YS=W+-*.]V?RE8DQ<7575>X M!O*5=2X

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, f

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

- RESPONSE TO SEC COMMENTS RE: FIRST AMENDED PROXY STATEMENT

begin 644 lettercytrx20200714.pdf M)5!$1BTQ+C,*)<3E\N7KI.@T,3&"C0@,"!O8FH*/#P@+TQE;F=T:" U(# @ M4B O1FEL=&5R("]&;&%T941E8V]D92 ^/@IS=')E86T*> &U7%ES'#>2?N]? M42;==(L6BX6Z2VZ.;$EMCVW)UW+6NVMY7APQ.[$A;<2$W$?IG(S$(!13:Z MI;4<[#H3B;P/H/Y5%S\J[A]^:NN/]'\5NQ^^3B27'C MBMVEGT2?%[NJ>@7>9GPF*X@7$C79FC*:NJ&%G(A#:H8(%$3I\R? QFUV3R%* M."AV-WI@5R ,N%4'MTIZ"1=N^>5B1^+(%ZHGH%5;[)P\4/.-X(*^V= #34%S M\6^V?( K'1\ D9

- 2020 CONTESTED PROXY STATEMENT - SECOND AMENDED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid

- 2020 CONTESTED PROXY STATEMENT - FIRST AMENDED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid

- 2020 PROXY CONTEST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

-

CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 ANNUAL MEETING OF STOCKHOLDERS to be held on July 30, 2020 Supplement to Proxy Statement dated June 12, 2020 CytRx Corporation (the “Company”) is filing this amendment and supplement (this “Supplement”) to its proxy statement dated June 12, 2020 (the “Proxy Statement”) in connection with the Company’s Annual Meeting of Stockholders to be held on July 30, 2020.

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 ANNUAL MEETING OF STOCKHOLDERS to be held on July 30, 2020 Supplement to Proxy Statement dated June 12, 2020

Exhibit 99.1 CytRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 ANNUAL MEETING OF STOCKHOLDERS to be held on July 30, 2020 Supplement to Proxy Statement dated June 12, 2020 CytRx Corporation (the “Company”) is filing this amendment and supplement (this “Supplement”) to its proxy statement dated June 12, 2020 (the “Proxy Statement”) in connection with the Company

-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,

-

PRE 14A 1 pre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Stateme

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2017 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation)

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to to Commission file number 0-15327 CytRx Corporatio

Employment Agreement with John Y. Caloz, dated January 8, 2020

Exhibit 10.1

CYTR / CytRx Corp. 10-K - Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation

Fifth Amendment to Office Lease dated January 13, 2020 by and between CytRx Corporation and Douglas Emmett 1993, LLC

Exhibit 10.4.3

CytRx Corporation Provides Update on Management Change

Exhibit 99.1 CytRx Corporation Provides Update on Management Change LOS ANGELES – March 10, 2020 – CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today announced that effective immediately, Mr. Eric Curtis, President and Chief Operating Officer of CytRx Corporation and President and CEO of C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2020 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

CYTR / CytRx Corp. 8-A12G/A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A/A (Amendment No.

January 23, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

SUMMARY OF RIGHTS TO PURCHASE SERIES B JUNIOR PARTICIPATING PREFERRED STOCK

Exhibit 99.1 SUMMARY OF RIGHTS TO PURCHASE SERIES B JUNIOR PARTICIPATING PREFERRED STOCK Effective December 13, 2019, the Board of Directors of CytRx Corporation (the “Company”) declared a dividend of one Right (a “Right”) for each outstanding share of Common Stock, $0.001 par value per share (the “Common Stock”), to stockholders of record at the close of business on December 23, 2019 (the “Record

First Amendment, dated December 19, 2019, to Amended and Restated Employment Agreement, dated March 26, 2019, by and between CytRx Corporation and Steven A. Kriegsman

Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this “Amendment”) is entered into as of December 13, 2019, between CytRx Corporation, a Delaware corporation (“Employer”), and Steven A. Kriegsman (“Employee”) in order to amend as follows that certain Amended and Restated Employment Agreement, effective as of March 26, 2019 (the “Employment Agreement”)

Certificate of Elimination of Designation of Series A Junior Participating Preferred Stock

Exhibit 3.2 CERTIFICATE OF ELIMINATION OF THE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF CYTRX CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware CytRx Corporation, a Delaware corporation (the “Corporation”), certifies as follows: 1. The Restated Certificate of Incorporation, as amended (the “Charter”), of the Corporation authorizes the issuance of

Certificate of Elimination of Series B Convertible Preferred Stock

Exhibit 3.3 CERTIFICATE OF ELIMINATION OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF CYTRX CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware CytRx Corporation, a Delaware corporation (the “Corporation”), certifies as follows: 1. The Restated Certificate of Incorporation, as amended (the “Charter”), of the Corporation authorizes the issuance of 833,333

Form of Rights Certificate

Exhibit 4.2 RIGHTS CERTIFICATE This certifies that , or its registered assigns, is the registered holder of the number of Rights set forth above, each of which entitles the holder thereof, subject to the terms, provisions and conditions of the Rights Agreement, dated as of December 13, 2019, as the same may be amended from time to time (the “Rights Agreement”), between CytRx Corporation, a Delawar

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

Certificate of Designation of B Junior Participating Preferred Stock

Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES B JUNIOR PARTICIPATING PREFERRED STOCK OF CYTRX CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware CytRx Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Company”), DOES HEREBY CERTIFY: That, pursuant to authority conferred by the Restated

Rights Agreement, dated as of December 13, 2019, by and between CytRx Corporation and American Stock Transfer & Trust Company, LLC, as rights agent.

Exhibit 4.1 CYTRX CORPORATION and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Rights Agent RIGHTS AGREEMENT dated as of December 13, 2019 TABLE OF CONTENTS Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 6 Section 3. Issue of Rights Certificates 6 Section 4. Form of Rights Certificate 8 Section 5. Countersignature and Registration 9 Section 6. Transfer, Split Up, C

Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

CytRx Corporation 2019 Stock Incentive Plan

CYTRX CORPORATION 2019 STOCK INCENTIVE PLAN 1. PURPOSE. (a) The purpose of the Plan is to provide to eligible recipients an opportunity to benefit from increases in value of the Common Stock through Stock Awards. (b) The Company, by means of the Plan, seeks to attract and retain the services of persons eligible to receive Stock Awards, to bind the interests of eligible recipients more closely to t

CYTR / CytRx Corp. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporati

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

CYTR / CytRx Corp. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (E

Other Events

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (

CYTR / CytRx Corp. DEFA14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

Letter of BDO USA, LLP dated June 24, 2019

CYTR / CytRx Corp. DEF 14A - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential,

CYTR / CytRx Corp. / SOON-SHIONG PATRICK - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytRx Corporation (Name of Issuer) Common Stock, Par value $0.001 per share (Title of Class of Securities) 232828608 (CUSIP Number) Patrick Soon-Shiong, M.D. ImmunityBio, Inc 9922 Jefferson Boulevard Culver City, California 90232 (310) 883-1300 Wit

CytRx Corporation to Commence Trading on OTCQB Venture Market Company to Continue Trading Under Ticker Symbol “CYTR”

CytRx Corporation to Commence Trading on OTCQB Venture Market Company to Continue Trading Under Ticker Symbol “CYTR” LOS ANGELES – May 31, 2019 — CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019, under the same ticker symbol “CYTR”.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Num

CYTR / CytRx Corp. 10-Q Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (

Amended and Restated Employment Agreement, dated March 26, 2019, by and between CytRx Corporation and Steven A. Kriegsman

Exhibit 10.18 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into as of the 26th day of March, 2019 (the “Effective Date”), by and between CytRx Corporation, a Delaware corporation (“Employer”), and Steven A. Kriegsman, an individual and resident of the State of California (“Employee”), with reference to the following

CYTR / CytRx Corp. (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2019 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

CYTR / CytRx Corp. 10-Q (Quarterly Report)

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-1

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File N

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 form8k2018q2.htm WEBCAST AND EARNINGS RELEASE FOR SECOND QUARTER 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327

CytRx Corporation Reports Second Quarter 2018 Financial Results Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET (8:00 am PT)

EXHIBIT 99.1 CytRx Corporation Reports Second Quarter 2018 Financial Results Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) LOS ANGELES – August 6, 2018 - CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ende

CYTR / CytRx Corp. 10-Q (Quarterly Report)

10-Q 1 form10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 C

CYTR / CytRx Corp. SUPPLEMENT TO DEFINITIVE 14A PROXY STATEMENT FIRST FILED JULY 5, 2018.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant R Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use

CYTR / CytRx Corp. DEF 14A

DEF 14A 1 def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Stateme

AMENDED AND RESTATED BY-LAWS CYTRX CORPORATION (a Delaware Corporation) REFLECTING AMENDMENTS THROUGH JUNE 18, 2018

EXHIBIT 99 AMENDED AND RESTATED BY-LAWS OF CYTRX CORPORATION (a Delaware Corporation) REFLECTING AMENDMENTS THROUGH JUNE 18, 2018 ARTICLE I STOCKHOLDERS 1.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Nu

CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

EXHIBIT 99.1 CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates Los Angeles – June 4, 2018 – CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned subsidiar

Financial Statements and Exhibits, Other Events

8-K 1 form8k-centurion.htm CURRENT REPORT ON FORM 8-K CONCERNING FORMATION OF SUBSIDIARY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware

Engagement Letter, dated May 10, 2018, by and between CytRx Corporation and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on May 16, 2018)

EXHIBIT 10.2 May 10, 2018 STRICTLY CONFIDENTIAL CytRx Corporation 11726 San Vicente Blvd., Suite 650 Los Angeles, CA 90049 Attn: John Y. Caloz, Chief Financial Officer Dear Mr. Caloz: This letter agreement (this "Agreement") constitutes the agreement between CytRx Corporation (the "Company") and H.C. Wainwright & Co., LLC ("Wainwright"), that Wainwright shall serve as the exclusive agent, advisor

Form of Securities Purchase Agreement, dated as of May 11, 2018, by and between CytRx Corporation and each purchaser party thereto (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on May 16, 2018)

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of May 11, 2018, between CytRx Corporation, a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" and collectively the "Purchasers"). WHEREAS, subject to the terms and conditions set for

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported): May 11, 2018 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-15327 (Commission File Number) 58-1642740 (I.

CytRx Announces $7.0 Million Registered Direct Offering

EXHIBIT 99.1 CytRx Announces $7.0 Million Registered Direct Offering LOS ANGELES, May 11, 2018 /PRNewswire/ - CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 5,600,000 shares of its comm

5,600,000 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-217184 PROSPECTUS SUPPLEMENT (To Prospectus dated April 21, 2017) 5,600,000 Shares of Common Stock We are offering 5,600,000 shares of our common stock, par value $0.001 per share, at an offering price of $1.25 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “CYTR.” On May 9, 2018, the closing price of our co

CytRx Reports First Quarter 2018 Financial Results

EXHIBIT 99 CytRx Reports First Quarter 2018 Financial Results LOS ANGELES – May 8, 2018 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended March 31, 2018, and provided an overview of recent accomplishments and plans for its research and development programs.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File Numb

CYTR / CytRx Corp. QUARTERLY REPORT ON SEC FORM 10-Q FOR QUARTER ENDED MARCH 31, 2018 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (Exac

CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient®, Doxil

EXHIBIT 99 CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient®, Doxil®, Velcade®and Benlysta® LOS ANGELES – May 3, 2018 – CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported): May 2, 2018 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-15327 (Commission File Number) 58-1642740 (I.R

CYTRX CORPORATION 97,929 Shares Common Stock

424B3 1 form424b304022018.htm FINAL PROSPECTUS FOR 97,929 SHARES. The named shareholders have no present intention to sell their shares under this prospectus. IN ADDITION, NEITHER SHAREHOLDER HAS EVER SOLD ANY CYTRX SHARES. Filed Pursuant to Rule 424(b)(3) Registration No. 333-223808 PROSPECTUS CYTRX CORPORATION 97,929 Shares Common Stock This prospectus relates to the offer for sale by the sellin

CYTR / CytRx Corp. CORRESP

March 27, 2018 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Registration Statement on Form S-3; File No. 333-223808 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, CytRx Corporation, a Delaware corporation, hereby requests that the Securities and Exchange Commission issue an order declaring the above

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8kkratz.htm DISCLOSURE OF EMPLOYMENT AGREEMENT WITH FELIX KRATZ, PH.D. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-1

EMPLOYMENT AGREEMENT

EXHIBIT 99.1 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is made and entered into as of March 16, 2018 (the "Effective Date") by and between CytRx Corporation, a Delaware corporation ("Employer"), and Felix Kratz, Ph.D., an individual and resident of Germany ("Employee"). WHEREAS, Employer desires to continue to employ Employee, and Employee is willing to continue to be emplo

CYTR / CytRx Corp. REGISTRATION OF UP TO 97,929 OUTSTANDING SHARES OF CYTRX COMMON STOCK.

As filed with the Securities and Exchange Commission on March 21, 2018 Reg. No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 58-1642750 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ident

POWER OF ATTORNEY

EX-24.1 4 exh24-1.htm POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven A. Kriegsman as his true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (in

CytRx Reports 2017 Financial Results Four New LADR™ Candidates with Breakthrough Potential Recently Selected for Advancement Into Investigational New Drug-Enabling Studies Company to Host Conference Call Today at 11:00 am ET (8:00 am PT)

EX-99.1 2 ex99-1.htm PRESS RELEASE DATED MARCH 19, 2018 EXHIBIT 99.1 CytRx Reports 2017 Financial Results Four New LADR™ Candidates with Breakthrough Potential Recently Selected for Advancement Into Investigational New Drug-Enabling Studies Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) LOS ANGELES – March 19, 2018 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File N

Employment Agreement dated January 10, 2019, between CytRx Corporation and John Y. Caloz

EX-10.30 2 exh10-30.htm 2018 EMPLOYMENT AGREEMENT FOR JOHN CALOZ Exhibit 10.30 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is made and entered into this February 26, 2018, with an effective date of Jamuary 1, 2018 (the "Effective Date") by and between CytRx Corporation, a Delaware corporation ("Employer"), and John Caloz, an individual and resident of the State of California

Annual Report on Form 10-K for the year ended December 31, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (Ex

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2018 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission Fil

POWER OF ATTORNEY

EX-24 2 powerofatty.htm POWER OF ATTORNEY: FELIX KRATZ. POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of John Y. Caloz and Cara Birardi, or either of them acting singly and with full power of substitution, as the true and lawful attorneys-in-fact and agents of the undersigned: (1) to prepare and execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Earliest Event Reported) November 8, 2017 CYTRX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-15327 (Commission File Number) 58-1642740

CytRx Reports Third Quarter 2017 Financial Results

Exhibit 99.1 CytRx Reports Third Quarter 2017 Financial Results LOS ANGELES ? November 8, 2017 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended September 30, 2017, and provided an overview of recent accomplishments and plans. "The third quarter of 2017 was transformative for Cy

CYTR / CytRx Corp. QUARTERLY REPORT ON FORM 10-Q FOR QUARTER ENDED 2017-09-30. (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (

CytRx Announces Strategic Realignment of Clinical Development Team

EXHIBIT 99.1 CytRx Announces Strategic Realignment of Clinical Development Team LOS ANGELES ? November 6, 2017 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the strategic realignment of its drug development efforts for advancing new drug candidates based on its LADR? (Linker Activated Drug Release) Technology Plat

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2017 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-1642740 (State or other jurisdiction of incorporation) (Commission File

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K 1 form8k11-01-2017.htm FORM 8-K COVERING REVERSE STOCK SPLIT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2017 CYTRX CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-15327 58-164274

CytRx Corporation Announces Results from Special Meeting of Stockholders Stockholders Approve Reverse Stock Split Proposal by More Than Double FOR to One AGAINST

EXHIBIT 99.1 CytRx Corporation Announces Results from Special Meeting of Stockholders Stockholders Approve Reverse Stock Split Proposal by More Than Double FOR to One AGAINST LOS ANGELES, October 27, 2017 - CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research and development company specializing in oncology, today announced the results of the Special Meeting of Stockholders which took p